Presentations & Publications

Presentation

A prospective phase 2 trial (GOG-0265) of the Listeria-based HPV immunotherapy axalimogene filolisbac (AXAL) in second- and third- line metastatic cervical cancer: An NRG Oncology Group trial

SGO, March 13, 2017

STAY TUNED

Mailing List

Sign up for email alerts for Press Releases & breaking Advaxis news.

SOCIAL

Follow Us

Stay up to date on the latest events, news, and happenings on Advaxis and Immunotherapy.